Simultaneous Detection for TB Infection and Resistance to RIF & NIH

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a global health threat. And the increasing resistance to key TB drugs like Rifampicin(RIF) and Isoniazid(INH) is critical and rising obstacle to global TB control efforts. Rapid and accurate molecular test of TB and resistance to RIF& INH is recommended by the WHO to identify the infected patients timely and provide them with appropriate in-time treatment.

Challenges

An estimated 10.6 million people fell ill with TB in 2021 with an increase of 4.5% from 10.1 million in 2020, resulting in an estimated 1.3 million deaths, equals to 133 cases per 100,000.

Drug-resistant TB, particularly MDR-TB (resistant to RIF & INH), is increasingly affecting the global TB treatment and prevention.

Rapid simultaneous TB and RIF/INH resistance diagnosis urgently required for earlier and more effective treatment compared with delayed drug susceptibility testing results.

Our Solution

Marco & Micro-Test’s 3-in-1 TB Detection for TB infection/RIF & NIH Resistance Detection Kit enables efficient diagnosis of TB and RIF/INH in one detection.

Melting curve technology realizes simultaneous detection of TB and MDR-TB.

3-in-1 TB/MDR-TB detection determining TB infection and key first-line drug (RIF/INH) resistance enables timely and accurate TB treatment. 

Mycobacterium Tuberculosis Nucleic Acid and Rifampicin, Isoniazid Resistance Detection Kit (Melting Curve)

Successfully realizes the triple TB testing (TB infection, RIF & NIH Resistance) in one detection!

Rapid result: Available in 1.5-2 hrs with automatic result interpretation minimizing technical training for operation;

Test Sample: 1-3 mL sputum;

High Sensitivity: Analytical sensitivity of 50 bacteria/mL for TB and 2x10³ bacteria/mL for RIF/INH resistant bacteria, ensuring reliable detection even at low bacterial loads.

Multiple Targets: TB-IS6110; RIF-resistance -rpoB (507~503);

INH-resistance- InhA/AhpC/katG 315;

Quality Validation: Cell control for sample quality validation to reduce false negatives;

Wide Compatibility: Compatibility with most mainstream PCR systems for wide lab accessibility;

WHO Guidelines Compliance: Adhering to WHO guidelines for the management of drug-resistant tuberculosis, ensuring reliability and relevance in clinical practice.